NASDAQ:ADMS Adamas Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adamas Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.73 +0.12 (+2.60 %) (As of 09/18/2020 12:34 PM ET) Add Compare Share Today's Range$4.57Now: $4.73▼$4.7850-Day Range$2.48MA: $4.39▼$5.4352-Week Range$1.90Now: $4.73▼$7.78Volume6,169 shsAverage Volume486,064 shsMarket Capitalization$133.77 millionP/E RatioN/ADividend YieldN/ABeta2.29 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAdamas Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.10, Adamas Pharmaceuticals has a forecasted upside of 93.2% from its current price of $4.71.Amount of Analyst CoverageAdamas Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAdamas Pharmaceuticals has received 393 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdamas Pharmaceuticals has received 321 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdamas Pharmaceuticals has received 55.04% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADMS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdamas Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdamas Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adamas Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 19.70% of the stock of Adamas Pharmaceuticals is held by insiders.Percentage Held by Institutions46.30% of the stock of Adamas Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.96) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adamas Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adamas Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.54 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMS Previous Symbol CUSIPN/A CIK1328143 Webwww.adamaspharma.com Phone510-450-3500Debt Debt-to-Equity RatioN/A Current Ratio5.83 Quick Ratio5.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$54.64 million Price / Sales2.45 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-157.67Profitability EPS (Most Recent Fiscal Year)($3.80) Net Income$-105,190,000.00 Net Margins-122.52% Return on Equity-806.54% Return on Assets-50.24%Miscellaneous Employees159 Outstanding Shares28,282,000Market Cap$133.77 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $4.73 +0.12 (+2.60 %) (As of 09/18/2020 12:34 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADMS News and Ratings via Email Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter. Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions How has Adamas Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)? Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADMS shares have increased by 54.4% and is now trading at $4.71. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Adamas Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adamas Pharmaceuticals. When is Adamas Pharmaceuticals' next earnings date? Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Adamas Pharmaceuticals. How were Adamas Pharmaceuticals' earnings last quarter? Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.24. The specialty pharmaceutical company earned $18.79 million during the quarter, compared to analyst estimates of $15.63 million. Adamas Pharmaceuticals had a negative net margin of 122.52% and a negative return on equity of 806.54%. View Adamas Pharmaceuticals' earnings history. What price target have analysts set for ADMS? 8 Wall Street analysts have issued twelve-month price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $16.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $9.10 in the next year. This suggests a possible upside of 93.2% from the stock's current price. View analysts' price targets for Adamas Pharmaceuticals. Are investors shorting Adamas Pharmaceuticals? Adamas Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 855,400 shares, a drop of 17.8% from the August 15th total of 1,040,000 shares. Based on an average daily volume of 591,700 shares, the short-interest ratio is presently 1.4 days. Approximately 3.8% of the company's shares are short sold. View Adamas Pharmaceuticals' Short Interest. Who are some of Adamas Pharmaceuticals' key competitors? Some companies that are related to Adamas Pharmaceuticals include Cue Biopharma (CUE), Pandion Therapeutics (PAND), Kala Pharmaceuticals (KALA), Viking Therapeutics (VKTX), Homology Medicines (FIXX), Odonate Therapeutics (ODT), Urogen Pharma (URGN), Altimmune (ALT), Beyondspring (BYSI), CymaBay Therapeutics (CBAY), Axovant Sciences (AXON), MannKind (MNKD), Avid Bioservices (CDMO), Rigel Pharmaceuticals (RIGL) and Amryt Pharma (AMYT). View all competitors. What other stocks do shareholders of Adamas Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Amarin (AMRN), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX) and Exelixis (EXEL). Who are Adamas Pharmaceuticals' key executives? Adamas Pharmaceuticals' management team includes the following people: Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)Ashleigh Barreto, Director of Corp. Communications & Investor RelationsMs. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49) What is Adamas Pharmaceuticals' stock symbol? Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS." Who are Adamas Pharmaceuticals' major shareholders? Adamas Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Opaleye Management Inc. (3.39%), Assenagon Asset Management S.A. (2.67%), Emerald Advisers LLC (2.38%), Emerald Mutual Fund Advisers Trust (2.21%), AQR Capital Management LLC (1.49%) and Nuveen Asset Management LLC (1.30%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View institutional ownership trends for Adamas Pharmaceuticals. Which major investors are selling Adamas Pharmaceuticals stock? ADMS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Deltec Asset Management LLC, Jacobs Levy Equity Management Inc., and SG Americas Securities LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, and Christopher B Prentiss. View insider buying and selling activity for Adamas Pharmaceuticals. Which major investors are buying Adamas Pharmaceuticals stock? ADMS stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Assenagon Asset Management S.A., AQR Capital Management LLC, Jane Street Group LLC, Bridgeway Capital Management Inc., Worth Venture Partners LLC, Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust. View insider buying and selling activity for Adamas Pharmaceuticals. How do I buy shares of Adamas Pharmaceuticals? Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adamas Pharmaceuticals' stock price today? One share of ADMS stock can currently be purchased for approximately $4.71. How big of a company is Adamas Pharmaceuticals? Adamas Pharmaceuticals has a market capitalization of $133.21 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe. What is Adamas Pharmaceuticals' official website? The official website for Adamas Pharmaceuticals is www.adamaspharma.com. How can I contact Adamas Pharmaceuticals? Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
